|
Name |
Deoxybrevianamide E
|
Molecular Formula | C21H25N3O2 | |
IUPAC Name* |
(3S,8aS)-3-[[2-(2-methylbut-3-en-2-yl)-1H-indol-3-yl]methyl]-2,3,6,7,8,8a-hexahydropyrrolo[1,2-a]pyrazine-1,4-dione
|
|
SMILES |
CC(C)(C=C)C1=C(C2=CC=CC=C2N1)C[C@H]3C(=O)N4CCC[C@H]4C(=O)N3
|
|
InChI |
InChI=1S/C21H25N3O2/c1-4-21(2,3)18-14(13-8-5-6-9-15(13)22-18)12-16-20(26)24-11-7-10-17(24)19(25)23-16/h4-6,8-9,16-17,22H,1,7,10-12H2,2-3H3,(H,23,25)/t16-,17-/m0/s1
|
|
InChIKey |
KUGNSEAHJVSMAJ-IRXDYDNUSA-N
|
|
Synonyms |
Deoxybrevianamide E; 34610-68-9; Desoxybrevianamide E; GJ20E60VAQ; (3S,8aS)-3-[[2-(2-methylbut-3-en-2-yl)-1H-indol-3-yl]methyl]-2,3,6,7,8,8a-hexahydropyrrolo[1,2-a]pyrazine-1,4-dione; Pyrrolo(1,2-a)pyrazine-1,4-dione, 3-((2-(1,1-dimethyl-2-propen-1-yl)-1H-indol-3-yl)methyl)hexahydro-, (3S,8aS)-; cyclo-2-(1,1-dimethylallyl)-L-tryptophyl-L-proline; cyclo-L-prolyl-2-(1,1-dimethylallyl)-L-tryptophan; L-Prolyl-2-(1,1-dimethylallyl)-L-tryptophan anhydride; (3S,8aS)-3-{[2-(2-methylbut-3-en-2-yl)-1H-indol-3-yl]methyl}hexahydropyrrolo[1,2-a]pyrazine-1,4-dione; UNII-GJ20E60VAQ; CHEBI:72948; DTXSID60956110; ZINC5355881; NSC789233; NSC-789233; HY-125538; CS-0092159; C20636; Q27140204; (3S,8aS)-3-[[2-(1,1-dimethylallyl)-1H-indol-3-yl]methyl]-2,3,6,7,8,8a-hexahydropyrrolo[1,2-a]pyrazine-1,4-dione; 1-Hydroxy-3-{[2-(2-methylbut-3-en-2-yl)-1H-indol-3-yl]methyl}-6,7,8,8a-tetrahydropyrrolo[1,2-a]pyrazin-4(3H)-one
|
|
CAS | 34610-68-9 | |
PubChem CID | 182203 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 351.4 | ALogp: | 3.5 |
HBD: | 2 | HBA: | 2 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 65.2 | Aromatic Rings: | 4 |
Heavy Atoms: | 26 | QED Weighted: | 0.829 |
Caco-2 Permeability: | -4.792 | MDCK Permeability: | 0.00002010 |
Pgp-inhibitor: | 0.912 | Pgp-substrate: | 0.003 |
Human Intestinal Absorption (HIA): | 0.005 | 20% Bioavailability (F20%): | 0.004 |
30% Bioavailability (F30%): | 0.005 |
Blood-Brain-Barrier Penetration (BBB): | 0.777 | Plasma Protein Binding (PPB): | 83.29% |
Volume Distribution (VD): | 0.809 | Fu: | 10.55% |
CYP1A2-inhibitor: | 0.094 | CYP1A2-substrate: | 0.555 |
CYP2C19-inhibitor: | 0.765 | CYP2C19-substrate: | 0.426 |
CYP2C9-inhibitor: | 0.465 | CYP2C9-substrate: | 0.882 |
CYP2D6-inhibitor: | 0.111 | CYP2D6-substrate: | 0.754 |
CYP3A4-inhibitor: | 0.928 | CYP3A4-substrate: | 0.651 |
Clearance (CL): | 1.826 | Half-life (T1/2): | 0.35 |
hERG Blockers: | 0.041 | Human Hepatotoxicity (H-HT): | 0.625 |
Drug-inuced Liver Injury (DILI): | 0.243 | AMES Toxicity: | 0.012 |
Rat Oral Acute Toxicity: | 0.926 | Maximum Recommended Daily Dose: | 0.694 |
Skin Sensitization: | 0.345 | Carcinogencity: | 0.141 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.011 |
Respiratory Toxicity: | 0.953 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC004933 | 1.000 | D05MQK | 0.298 | ||||
ENC004929 | 0.721 | D08VRO | 0.289 | ||||
ENC004930 | 0.697 | D09ZIO | 0.289 | ||||
ENC001926 | 0.690 | D0U7GP | 0.287 | ||||
ENC002631 | 0.655 | D01JGV | 0.287 | ||||
ENC002925 | 0.640 | D0U7GK | 0.286 | ||||
ENC004932 | 0.640 | D0H4JM | 0.276 | ||||
ENC000975 | 0.614 | D0Q5NX | 0.273 | ||||
ENC003217 | 0.595 | D02DMQ | 0.269 | ||||
ENC005484 | 0.543 | D04ACW | 0.265 |